drugset / Trial / NCT01888445

A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

NCT01888445

Phase 2 Completed 130 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate safety and efficacy of intermittent oral dosing of ASP1517 in dialysis chronic kidney disease patients with anemia.

Timeline

Start
2013-03-28
Primary completion
2014-09-15
Completion
2014-09-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darbepoetin alfa Protein / enzyme biologic Intravenous
Subject Roxadustat Small molecule Oral